Original Article
Application of the superior thyroid artery peak systolic velocity in differentiating Graves′ disease from autoimmune thyroiditis
Wang Chen, Zhu Yu, Zhou Lingli, Zhao Yunyun, Han Xueyao, Ji Linong
Published 2020-03-01
Cite as Chin J Intern Med, 2020, 59(3): 207-212. DOI: 10.3760/cma.j.issn.0578-1426.2020.03.007
Abstract
ObjectiveTo evaluate the clinical value of the superior thyroid artery peak systolic velocity (STA-PSV) for the differential diagnosis of autoimmune thyrotoxicosis.
MethodsA total of 301 patients with newly diagnosed thyrotoxicosis and without any anti-thyroid drug intervention were collected from the Department of Endocrinology and Metabolism, Peking University People′s Hospital from Jan. 2015 to Oct. 2018. Among them, 241 patients were with Graves′ disease (GD) and 60 patients were with autoimmune thyroiditis (AIT). STA-PSV, thyroid function and thyrotropin receptor antibody (TRAb) were determined. A multiple linear regression was used to identify factors associated with STA-PSV. A receiver operating characteristic (ROC) curve and area under the curve (AUC) were used to evaluate the discriminating ability of STA-PSV to GD.
ResultsSTA-PSV leves in GD group were significantly higher than those in AIT group [61.00 (41.00, 86.50) cm/s vs. 34.50 (25.25, 46.00) cm/s, P<0.001]. The ROC curve analysis showed that the AUC was 0.790 (95%CI 0.734-0.845), and 49.5cm/s was the optimal cutoff point for the diagnosis of GD, in which the sensitivity was 64.3% and the specificity was 83.3%. In all patients with thyrotoxicosis, multiple linear regression analyses showed free thyroxine (FT4) (β=0.371, 95%CI 0.005-0.010, P<0.001) and TRAb (β=0.138, 95%CI 0.001-0.014, P=0.035) were positively associated with STA-PSV.
ConclusionsThe STA-PSV is positively associated with FT4 and TRAb levels, and it is a helpful marker in differential diagnosis between GD and AIT.
Key words:
Graves disease; Thyroiditis, autoimmune; Thyrotoxicosis; Blood flow velocity
Contributor Information
Wang Chen
Department of Endocrinology and Metabolism, Peking University People′s Hospital, Beijing 100044, China(is working on Department of Endocrinology, Tangshan People′s Hospital, Tangshan 063000, China)
Zhu Yu
Department of Endocrinology and Metabolism, Peking University People′s Hospital, Beijing 100044, China
Zhou Lingli
Department of Endocrinology and Metabolism, Peking University People′s Hospital, Beijing 100044, China
Zhao Yunyun
Department of Nuclear Medicine, Peking University People′s Hospital, Beijing 100044, China
Han Xueyao
Department of Endocrinology and Metabolism, Peking University People′s Hospital, Beijing 100044, China
Ji Linong
Department of Endocrinology and Metabolism, Peking University People′s Hospital, Beijing 100044, China